laboratory diagnostics, such as qPCR and ELISA, have been successful in providing earlier diagnoses. However, the sensitivity of these assays may limit the effectiveness of these methods and thereby underrepresent the prevalence of infections such as KSHV and EBV in the human population. Currently, the most common method is the detection of antibodies produced in response to viral infection (i.e. seropositivity). Regardless, the robustness and stability of miRNAs makes them the ideal choice for diagnostic targets.
In a recent article published in EBioMedicine, Fuentes-Mattei and colleagues examined plasma samples from four independent patient cohorts with post-surgical/post-chemotherapy sepsis, chronic lymphocytic leukemia, and post-abdominal surgery were examined to compare the prevalence of KSHV as determined by seropositivity vs. prevalence determined by viral miRNA qPCR (CtN 35) (Fuentes-Mattei et al., 2017) . Overall analysis of all four independent cohorts (n = 214) showed qPCR-detectable expression of a single KSHV miRNA, either KSHV-miR-K12-10b, KSHV-miR-K12-12, or KSHV-miR-K12-4-3p, in 78.50% of patients though 27.57% of patients tested seropositive for KSHV IgG. For a better correlation to clinical outcomes, viral miRNAs were detected in 90.48% of patients with a low WBC count (WBC b 400 cells/μl) and in 92.59% of patients with a low lymphocyte count (LYM b 1000 cells/μl), suggesting the detection power was significantly higher than ELISA detection of KSHV IgG antigen (14.29% and 18.52% respectively). The study concluded that the prevalence of KSHV infection is much greater than previously thought when utilizing ELISA diagnostic methods, and that use of miRNAs for diagnosis was significantly more accurate (Fuentes-Mattei et al., 2017) .
To confirm significance of the discrepancy between these two diagnostic methods, Fuentes-Mattei et al. went on to analyze the same independent patient cohorts for the prevalence of EBV, as this virus has been shown to have a higher prevalence in the human population (Fuentes-Mattei et al., 2017) . Analysis showed detectable expression of a single EBV miRNA, either EBV-miR-BART4 or EBV-miR-BHRF1-1, in 98.99% of patients while Epstein-Barr virus nuclear antigen 1 (EBNA-1) IgG seropositivity was found in 95.97% of the cohort. However, when patients with cases of low lymphocyte counts were tested, 92.59% of cases tested positive for EBV miRNAs, while only 62.96% tested positive for EBNA-1 IgG, further supporting the increased diagnostic resolution of miRNAs over seropositivity methods (Fuentes-Mattei et al., 2017) .
Many human viruses of clinical importance including polyomaviruses, hepatitis B virus, hepatitis C virus, human papillomavirus, human immunodeficiency virus produce viral miRNAs (Louten et al., 2015) . These specific viral miRNAs have likewise been explored as potential diagnostic platforms (Lagatie et al., 2014; Zhu et al., 2017; Takahashi et al., 2013;  
